Related Experiment Videos
Postnatal triiodothyronine replacement and respiratory distress syndrome of the preterm infant
M Amato1, C Guggisberg, H Schneider
1Department of Obstetrics and Gynecology, University of Berne, Switzerland.
Insights
Postnatal triiodothyronine (T3) administration showed a slight benefit in reducing oxygen needs for preterm infants with respiratory distress syndrome (RDS). Further research is needed to confirm its impact on overall outcomes.
Area of Science:
- Neonatal Medicine
- Pediatric Endocrinology
- Pulmonary Medicine
Background:
- Respiratory distress syndrome (RDS) is common in preterm infants.
- Low circulating triiodothyronine (T3) levels in RDS may impair surfactant production.
- Hepatic conversion of thyroxine (T4) to T3 is often reduced in premature neonates.
Purpose of the Study:
- To investigate the effect of intravenous L-T3 administration on the clinical course of RDS in preterm infants.
- To evaluate if T3 supplementation improves outcomes in neonates with respiratory distress syndrome.
Main Methods:
- A randomized controlled trial involving 50 preterm infants (<32 weeks gestation) with RDS.
- Infants were randomly assigned to receive L-T3 (Thyrotardin) or a placebo.
- Outcomes assessed included mortality, oxygen requirements, ventilation duration, and RDS complications.
Main Results:
- No statistically significant differences were observed in mortality, ventilation duration, or complication rates between groups.
- A statistically significant reduction in fractional inspired oxygen (FiO2) concentrations was noted in the T3-treated group (p < 0.05).
Conclusions:
- Intravenous T3 replacement therapy may offer a relative benefit in managing RDS by reducing oxygen requirements in preterm infants.
- The study suggests a potential role for T3 in improving respiratory support for very preterm neonates, though major clinical outcomes were not significantly altered.
Abstract:
Improvements in the management of respiratory distress syndrome (RDS) include pre- and postnatal stimulation of pulmonary maturity, and triiodothyronine (T3) is believed to influence directly surfactant production. Its circulating levels are low in premature infants with RDS probably due to a low thyroxine T4-T3 hepatic conversion mechanism. While a state of hypotriiodothyroninemia exists at birth, we studied the influence of postnatal intravenous T3 administration on the course of RDS in preterm infants of less than 32 weeks' gestation. Fifty preterm infants with RDS were studied (mean gestational age 30.4 +/- 1.2 weeks and birth weight 1,180 +/- 220 g). They were at random assigned to treatment with 50 micrograms L-T3 (Thyrotardin) or to the control group. Mortality rate, peak oxygen concentrations, duration of artificial ventilation and development of major complications of RDS were the criteria to estimate the influence of T3 treatment on RDS. We failed to detect a statistically significant difference between the two groups in all of the mentioned criteria except for FiO2 concentrations required to maintain PaO2 between 50 and 60 mm Hg (p less than 0.05). These observations suggest a relative beneficial effect of T3 replacement on the course of RDS in preterm infants of less than 32 weeks of gestation.